Erika Roberts

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study

Christopher Tehlirian, Ravi Shankar Prasad Singh, Vivek Pradhan et al. · Journal of the American Academy of Dermatology · 2022 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study

Christopher Tehlirian, Elena Peeva, Elizabeth Kieras et al. · The Lancet Rheumatology · 2020 · 32 citations

Medicine, Pharmacokinetics, Pharmacology +10

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study

Ravi Shankar Prasad Singh, Vivek Pradhan, Erika Roberts et al. · Clinical and Translational Science · 2020 · 27 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Hsp70—A Universal Biomarker for Predicting Therapeutic Failure in Human Female Cancers and a Target for CTC Isolation in Advanced Cancers

Alexia Xanthopoulos, Ann-Kathrin Samt, Christiane Guder et al. · Biomedicines · 2023 · 18 citations · Full text

Medicine, Cell Biology, Oncology +17

Practical and Statistical Considerations for the Long Term Follow‐Up of Gene Therapy Trial Participants

Maximilian Rohde, Seoan Huh, Vanessa D'Souza et al. · Clinical Pharmacology & Therapeutics · 2023 · 15 citations

Medicine, Biotechnology, Pharmacology +17